SELLAS Stock Surges 156% as Cancer Vaccine Meets Phase 3 Survival Goal

SELLAS Life Sciences Group logo prominently displayed against a stock market trading floor with financial charts
│
Published: November 17, 2026, 4:49 p.m. ET

SELLAS Life Sciences Group (NASDAQ: SLS) shares surged 156.36% to close at $19.15 on Tuesday after its experimental cancer vaccine, galinpepimut-S (GPS), met the primary overall-survival endpoint in a pivotal Phase 3 trial involving patients with acute myeloid leukemia (AML).

In the 126-patient REGAL trial, median overall survival was 24.0 months for patients treated with GPS, compared with 14.7 months for those receiving investigator-selected best available treatment, representing a 9.3-month survival advantage.

The survival difference was statistically significant (two-sided p = 0.035). The trial reported a hazard ratio of 0.59, indicating a 41% lower hazard of death in the GPS group compared with the control group. The primary analysis was conducted after 80 deaths, reaching the prespecified threshold for evaluating the trial’s primary endpoint.

The trial enrolled AML patients who achieved a second or subsequent complete remission, with or without full platelet recovery, after receiving second- or later-line salvage therapy. At enrollment, they were ineligible for or unable to undergo a donor stem-cell transplant.

Patients were randomly assigned in equal proportions to receive GPS maintenance therapy or investigator-selected best available treatment. The study was open-label, meaning patients and investigators knew which treatment each patient received.

Patients in the comparison group could receive observation or treatment with hypomethylating agents, venetoclax, or low-dose cytarabine, either alone or in combination. GPS, meanwhile, was administered alone and is designed to stimulate an immune response against leukemia cells by targeting the WT1 protein.

On safety, SELLAS reported that GPS was generally well tolerated, with no new safety signals identified. Most treatment-related adverse events were mild to moderate and primarily involved injection-site reactions.

However, the initial announcement did not include a confidence interval for the hazard ratio, which would help establish the precision of the estimated treatment effect. Detailed results for secondary endpoints, including leukemia-free survival, and analyses of prespecified patient subgroups remain pending. The company plans to present the comprehensive findings at a future medical conference and submit them for publication in a peer-reviewed journal.

SELLAS Targets FDA Application in First Half of 2027

Following the positive Phase 3 results, SELLAS said it plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy. The company is also preparing to file a Biologics License Application (BLA) in the first half of 2027 to seek approval to market GPS in the United States.

During a company webcast, management said SELLAS was advancing manufacturing, regulatory and potential commercial-launch preparations.

GPS remains investigational and has not received FDA approval. SELLAS has not yet submitted its planned application, and any approval will depend on the FDA’s review of the supporting evidence.

SLS Stock Snapshot: Rally Ends Three-Day Losing Streak

Tuesday’s rally reversed three consecutive trading sessions of declines, during which SLS shares had lost approximately 11.3% of their value.

The stock reached a new 52-week high of $24.89 during the session before closing approximately 23.1% below that peak. Trading was temporarily halted twice due to volatility, at around 9:35 a.m. and 9:50 a.m. Eastern Time.

At the close, SLS shares had gained about 408% year-to-date and 1,258% over the past year, based on historical closing prices.

Related Coverage

Related Healthcare Articles